2395.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 11:45):

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally...

Stats
आज की मात्रा	236 800
औसत मात्रा	279 423
बाजार मूल्य	57.24B
EPS	¥0 ( 2024-05-08 )
अगली कमाई की तारीख	( ¥0 ) 2024-07-30
Last Dividend	¥30.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	10.35
ATR14	¥0.972 (0.07%)

मात्रा सहसंबंध

लंबा: 0.05 (neutral)

छोटा: 0.17 (neutral)

Signal:(63.925) Neutral

Shin Nippon Biomedical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Shin Nippon Biomedical सहसंबंध - मुद्रा/वस्त्र

-0.72
( moderate negative )

-0.49
( neutral )

-0.66
( moderate negative )

-0.83
( strong negative )

-0.12
( neutral )

0.77
( moderate )

Shin Nippon Biomedical वित्तीय

Annual	2023
राजस्व:	¥26.45B
सकल लाभ:	¥14.02B (53.01 %)
EPS:	¥132.86

FY	2023
राजस्व:	¥26.45B
सकल लाभ:	¥14.02B (53.01 %)
EPS:	¥132.86

FY	2022
राजस्व:	¥25.09B
सकल लाभ:	¥13.05B (52.00 %)
EPS:	¥145.57

FY	2022
राजस्व:	¥17.75B
सकल लाभ:	¥9.69B (54.58 %)
EPS:	¥171.20

Financial Reports:

No articles found.

Shin Nippon Biomedical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥20.00 (N/A)	¥0 (N/A)	¥30.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Shin Nippon Biomedical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.01 - good (90.10%) | Divividend Growth Potential Score: 5.23 - Stable (4.67%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥0.500	2004-03-26
Last Dividend	¥30.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	15	--
Total Paid Out	¥99.00	--
Avg. Dividend % Per Year	0.00%	--
Score	2.49	--
Div. Sustainability Score	9.01
Div.Growth Potential Score	5.23
Div. Directional Score	7.12	--

Next Divdend (Est)
(2024-07-08)

¥0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

2.49

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8140.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7494.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6718.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6062.T	Ex Dividend Knight	2024-06-27	Annually	0.00%
4743.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
3984.T	Ex Dividend Junior	2024-06-27	Annually	0.00%
3193.T	Ex Dividend Knight	2024-01-30	Annually	0.00%
2183.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
9058.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7944.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.209	1.500	5.82	8.73	[0 - 0.5]
returnOnAssetsTTM	0.0725	1.200	7.58	9.10	[0 - 0.3]
returnOnEquityTTM	0.181	1.500	9.10	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.308	0.800	8.46	6.77	[1 - 3]
quickRatioTTM	0.693	0.800	-0.629	-0.503	[0.8 - 2.5]
cashRatioTTM	0.436	1.500	8.69	10.00	[0.2 - 2]
debtRatioTTM	0.340	-1.500	4.33	-6.49	[0 - 0.6]
interestCoverageTTM	28.11	1.000	0.701	0.701	[3 - 30]
operatingCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.761	-1.500	6.95	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.530	1.000	4.50	4.50	[0.2 - 0.8]
operatingProfitMarginTTM	0.147	1.000	9.05	9.05	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.138	1.000	-0.347	-0.347	[0.2 - 2]
assetTurnoverTTM	0.347	0.800	-1.022	-0.818	[0.5 - 2]
Total Score				9.01

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.35	1.000	9.06	0	[1 - 100]
returnOnEquityTTM	0.181	2.50	9.42	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.64	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0846	1.500	-3.90	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.135	1.000	9.12	0	[0.1 - 0.5]
Total Score				5.23

Shin Nippon Biomedical Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Shin Nippon Biomedical

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.